6 research outputs found
Kaplan Meier survival analyses of patients with high (solid) and low (dashed) cell infiltration in the tumor
<p><b>Copyright information:</b></p><p>Taken from "Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival"</p><p>http://www.translational-medicine.com/content/5/1/62</p><p>Journal of Translational Medicine 2007;5():62-62.</p><p>Published online 29 Nov 2007</p><p>PMCID:PMC2212626.</p><p></p> A) Patients with high S100 infiltration have a significantly better survival (p = 0.03). B) Patients with high total CD163 tend to have a better survival (p = 0.07). C) Patients with high stromal CD163 infiltration have a significantly better survival (p = 0.01)
Kaplan–Meier estimates of tumor related survival measured from the date of first admission stratified by vein invasion status V0 (red) /V1(blue) (left panel) and poorly differentiated medullary cancer (PMC) (blue) vs. other histopathological subtypes (no-PMC) (red) (right panel).
<p>Kaplan–Meier estimates of tumor related survival measured from the date of first admission stratified by vein invasion status V0 (red) /V1(blue) (left panel) and poorly differentiated medullary cancer (PMC) (blue) vs. other histopathological subtypes (no-PMC) (red) (right panel).</p
Patient characteristics collected from the patient management software and the regional population-based cancer registry (n = 129).
<p>Patient characteristics collected from the patient management software and the regional population-based cancer registry (n = 129).</p
Immunohistochemical biomarker analysis: All immunohistochemical markers except Ki-67, TP53, and Survivin were analyzed using the semiquantitative scoring system described in the method section.
<p>Immunohistochemical biomarker analysis: All immunohistochemical markers except Ki-67, TP53, and Survivin were analyzed using the semiquantitative scoring system described in the method section.</p
Immunhistochemical and H&E staining of the TMA of gastric cancer specimens (200x).
<p>Poorly differentiated medullary cancer by H&E staining (A) and CD3 staining (B). TP53 mutated (C) and wildtype (D) tumor sample.</p
Histopathological characteristics of the 80 tumor samples reevaluated from available formalin-fixed paraffin-embedded tissue samples.
<p>PMC: Poorly differentiated medullary cancer.</p